What is the clinical evidence from this study?

Study design: RCT. Population: Cardiovascular disease with elevated hs-CRP (n=125). Intervention: Pioglitazone and simvastatin combination vs. Simvastatin or pioglitazone monotherapy. Primary outcome: Changes in hs-CRP (p=<0.001).

What question did this study set out to answer?

To evaluate the safety and anti-inflammatory efficacy of combining pioglitazone and simvastatin versus each monotherapy in non-diabetic patients with cardiovascular disease and elevated high-sensitivity C-reactive protein.

April 25, 2026Journal of the American College of Cardiology

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein

Q: What are the key findings of this study?

The combination of pioglitazone and simvastatin reduced hs-CRP from 3.49 to 2.06 mg/l at 12 weeks, showing an additive anti-inflammatory effect over monotherapies (p<0.001).

Q: What question did this study set out to answer?

To evaluate the safety and anti-inflammatory efficacy of combining pioglitazone and simvastatin versus each monotherapy in non-diabetic patients with cardiovascular disease and elevated high-sensitivity C-reactive protein.

View Full Paper

Ask AI

Bookmark

Key result

Pioglitazone plus simvastatin reduces hs-CRP by ~41% more than monotherapy at 12 weeks.

P<0.001
n=125

Why the study?

Low-grade inflammation contributes to atherosclerosis, and the combined anti-inflammatory effects of pioglitazone and simvastatin in non-diabetic CVD patients with elevated hs-CRP were not established.

Does the combination of pioglitazone and simvastatin reduce hs-CRP more than either drug alone in non-diabetic patients with CVD and elevated hs-CRP?

Key Points

To evaluate the safety and anti-inflammatory efficacy of combining pioglitazone and simvastatin versus each monotherapy in non-diabetic patients with cardiovascular disease and elevated high-sensitivity C-reactive protein.
Conducted a 12-week, prospective, double-blind trial randomizing 125 non-diabetic subjects with cardiovascular disease to simvastatin plus placebo, pioglitazone plus placebo, or combination therapy.
Assessed changes in high-sensitivity C-reactive protein (hs-CRP) using analysis of covariance alongside subgroup assessments based on metabolic syndrome status.
Evaluated secondary endpoints including changes in PAI-1, MMP-9, and correlation to insulin resistance (HOMA) via Spearman's rank test.
Combination therapy produced an additive reduction in hs-CRP from 3.49 ± 1.97 mg/l to 2.06 ± 1.42 mg/l (p < 0.001), compared to monotherapy reductions with pioglitazone (3.64 ± 2.42 to 2.48 ± 1.77 mg/l) and simvastatin (3.26 ± 2.02 to 2.81 ± 2.11 mg/l).
HOMA scores improved in subjects receiving pioglitazone, showing a significant positive correlation between changes in HOMA and hs-CRP (r = 0.43; p < 0.05).
Both PAI-1 and MMP-9 decreased significantly only in the pioglitazone-containing groups, with no treatment-related serious adverse events across any group.

Study Design

Type

RCT (n=125)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does the combination of pioglitazone and simvastatin reduce hs-CRP more than either drug alone in non-diabetic patients with CVD and elevated hs-CRP?

Population

125 non-diabetic subjects with cardiovascular disease and elevated hs-CRP levels, followed for 12 weeks.

Intervention

Simvastatin and pioglitazone combination therapy for 12 weeks

Comparator

Simvastatin plus placebo or pioglitazone plus placebo (monotherapies)

Outcome

Changes in hs-CRP at 12 weekssurrogate

Main Result

p-value: p=<0.001

The combination of pioglitazone and simvastatin provides additive anti-inflammatory effects compared to monotherapy in non-diabetic patients with CVD and elevated hs-CRP.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May offer superior anti-inflammatory control with pioglitazone-simvastatin in non-diabetic CVD; extends RCT surrogate evidence but leaves open clinical outcomes.

Cite This Study

Hanefeld et al. (2007) conducted an RCT in Cardiovascular disease with elevated hs-CRP (n=125). Pioglitazone and simvastatin combination vs. Simvastatin or pioglitazone monotherapy was evaluated on Changes in hs-CRP (p=<0.001). The combination of pioglitazone and simvastatin reduced hs-CRP from 3.49 to 2.06 mg/l at 12 weeks, showing an additive anti-inflammatory effect over monotherapies (p<0.001).

synapsesocial.com/papers/69ecdb66eb2c6328dba62cd9 https://doi.org/10.1016/j.jacc.2006.08.054

View Full Paper

Ask AI

Bookmark

Implication

May offer superior anti-inflammatory control with pioglitazone-simvastatin in non-diabetic CVD; extends RCT surrogate evidence but leaves open clinical outcomes.

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider